FOXD3 and breast cancer: The present study demonstrated that FOXD3-AS1 may be associated with anti-estrogen therapy resistance of BC cells, with the FOXD3-AS1/miR-363/TFF1 ceRNA network and the PI3K/Akt signaling pathway possibly being involved in the process.